Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

USA - NASDAQ:CNSP - US18978H5081 - Common Stock

10 USD
+0.52 (+5.49%)
Last: 10/7/2025, 3:24:01 PM
Fundamental Rating

2

CNSP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. The financial health of CNSP is average, but there are quite some concerns on its profitability. CNSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNSP had negative earnings in the past year.
In the past year CNSP has reported a negative cash flow from operations.
In the past 5 years CNSP always reported negative net income.
CNSP had a negative operating cash flow in each of the past 5 years.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CNSP has a Return On Assets of -106.55%. This is in the lower half of the industry: CNSP underperforms 78.06% of its industry peers.
Looking at the Return On Equity, with a value of -117.78%, CNSP is doing worse than 63.78% of the companies in the same industry.
Industry RankSector Rank
ROA -106.55%
ROE -117.78%
ROIC N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

CNSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

CNSP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CNSP has more shares outstanding
The debt/assets ratio for CNSP has been reduced compared to a year ago.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.94, we must say that CNSP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CNSP (-8.94) is worse than 66.33% of its industry peers.
CNSP has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CNSP has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CNSP outperforms 57.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.94
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

CNSP has a Current Ratio of 10.22. This indicates that CNSP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CNSP (10.22) is better than 82.14% of its industry peers.
A Quick Ratio of 10.22 indicates that CNSP has no problem at all paying its short term obligations.
The Quick ratio of CNSP (10.22) is better than 82.14% of its industry peers.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.22
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.65% over the past year.
EPS 1Y (TTM)99.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNSP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.81%
EPS Next 2Y40.65%
EPS Next 3Y25.58%
EPS Next 5Y18.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -100K -200K -300K -400K -500K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CNSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

A more expensive valuation may be justified as CNSP's earnings are expected to grow with 25.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.65%
EPS Next 3Y25.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNSP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (10/7/2025, 3:24:01 PM)

10

+0.52 (+5.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners7.44%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap5.70M
Analysts82.5
Price Target53.04 (430.4%)
Short Float %9.44%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-38.1%
PT rev (3m)642.86%
EPS NQ rev (1m)6.15%
EPS NQ rev (3m)-1026.19%
EPS NY rev (1m)87.55%
EPS NY rev (3m)-49.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-276.72
EYN/A
EPS(NY)-10.38
Fwd EYN/A
FCF(TTM)-36.6
FCFYN/A
OCF(TTM)-36.59
OCFYN/A
SpS0
BVpS23.03
TBVpS23.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.55%
ROE -117.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.22
Altman-Z -8.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)74.13%
Cap/Depr(5y)104.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
EPS Next Y92.81%
EPS Next 2Y40.65%
EPS Next 3Y25.58%
EPS Next 5Y18.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.89%
OCF growth 3YN/A
OCF growth 5YN/A